News
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
July 15, 2010 2:38 pm | by Bio-Medicine.Org | Comments- Treatment with Nypta(R) (Tideglusib) (NP-12) was tolerated and produced positive effects on Alzheimer's patients in four of the five efficacy variables examined in the trial. - In view of the promising results of this trial, Noscira is preparing the next Phase IIb trial on Alzheimer's...
Dynatronics Launches E-Commerce Website
July 15, 2010 2:38 pm | by Bio-Medicine.Org | CommentsSALT LAKE CITY , July 15 /- Dynatronics Corporation (Nasdaq: DYNT ) today announced the launch of its e-commerce website at dynatronics.com . The new website offers thousands of products for clinics and medical practitioners, particularly targeting the physical medicine market. "The...
New method of tissue banking makes gene analysis more practical for lung cancer
July 15, 2010 2:35 pm | by EurekAlert | Comments(International Association for the Study of Lung Cancer) Analyzing the genes expressed by cancer cells allows for a better understanding of that patient's specific disease and in turn, a more personalized approach to treatment. But obtaining the RNA from a tumor in the lungs in...
AngioDynamics fiscal 4Q net income up 29 percent
July 15, 2010 1:45 pm | by The Associated Press | CommentsMedical device maker AngioDynamics Inc. said Thursday its fiscal fourth-quarter net income rose 29 percent, helped by higher sales of peripheral vascular, and oncology and surgery products.For the three months ended May 31, AngioDynamics' net income increased to $3.7 million, or 15 cents per...
AngioDynamics' profit guidance lower than expected
July 15, 2010 1:45 pm | by The Associated Press | CommentsMedical device maker AngioDynamics Inc. issued earnings guidance Thursday that is lower than Wall Street is expecting, but revenue guidance range was higher than analysts' average forecast.AngioDynamics said it expects net income of 53 cents to 56 cents per share for the fiscal year, which ends...
Class I Medical Device Recall: Symbiq One-Channel Infuser and Symbiq Two-Channel Infuser
July 15, 2010 12:32 pm | by U.S. Food & Drug Administration | CommentsThere is potential for the device to fail to detect air in line at the end of an infusion.
Angiotensin Receptor Blockers (ARBs): Ongoing Safety Review for Cancer Risk(2)
July 15, 2010 12:31 pm | by U.S. Food & Drug Administration | CommentsA recently published study suggested use of ARBs may be associated with a small increased risk of cancer.
Angiotensin Receptor Blockers (ARBs): Ongoing Safety Review for Cancer Risk
July 15, 2010 12:31 pm | CommentsA recently published study suggested use of ARBs may be associated with a small increased risk of cancer.
Cardinal Health closes Healthcare Solutions buyout
July 15, 2010 11:45 am | by The Associated Press | CommentsHealth care products distributor Cardinal Health Inc. said Thursday it completed its $517 million acquisition of Healthcare Solutions Holding LLC.Healthcare Solutions is the parent company of P4 Pathways and P4 Healthcare, which provide tools and services to specialty care doctors, drug...
Bell Medical and ITelagen Welcome Final Rule for 'Meaningful Use' of Electronic Health Records
July 15, 2010 10:38 am | by Bio-Medicine.Org | CommentsJERSEY CITY, N.J. , July 15 /- ITelagen, Inc., innovative provider of healthcare information technology, medical billing and electronic health records (EHR), and Bell Medical Services, Inc., a leading regional distributor of medical supplies, equipment and pharmaceuticals welcome the US...
Caliper Life Sciences hit with IP lawsuit
July 15, 2010 10:36 am | by Mass High Tech: The Journal of New England Technology | CommentsCaliper Life Sciences has been sued for patent infringement by Carestream Health Inc. in the U.S. District Court for the Western District of Wisconsin Madison Division.
Merz Aestheticsâ„¢ Ascleraâ„¢ (polidocanol) Injection Now Available in Doctors' Offices Nationwide
July 15, 2010 10:36 am | by Bio-Medicine.Org | CommentsSAN MATEO, Calif. , July 15 /- Merz Aesthetics today announced it is now shipping Asclera™ (polidocanol) Injection sclerotherapy treatment to doctors' offices throughout the U.S. Previously only available in Europe , Asclera™ was recently approved by the U.S. Food and...
MGH, Harvard researchers develop 'artificial lung'
July 15, 2010 10:35 am | by Mass High Tech: The Journal of New England Technology | CommentsResearchers at Massachusetts General Hospital and Harvard Medical School developed an artificial lung that helped rats breathe for about six hours.
The probability of surviving nine types of cancer is analyzed
July 15, 2010 10:35 am | by EurekAlert | Comments(FECYT - Spanish Foundation for Science and Technology) Spanish epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries. At five years from diagnosis, the lowest survival rate is observed in lung...
Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
July 15, 2010 10:34 am | by Bio-Medicine.Org | CommentsIRVINE, California , and AMSTERDAM , July 15, 2010 /- Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed...
